YMYoichi Mizutani

Yoichi Mizutani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoichi Mizutani has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Recent advances in molecular targeted therapy for metastatic renal cell carcinoma

    by Yoichi Mizutani

    Advanced renal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy. Immunotherapy is relatively effective against RCC. However, the response rate is approximately 15-20%. Therefore, new therapeutic approaches are necessary. Recently, molecular mechanisms responsible for the proliferation of RCC are identified, and molecular targeted therapy is developed. Bevacizumab, sorafenib, sunitinib, axitinib, temsirolimus, everolimus are promising molecular targeted therapeutic agents for metastatic RCC, and will be used widely in clinics in the near future. In addition, combination therapy with molecular targeted therapy and other therapies including immunotherapy may also be developed soon.


  • Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Cancer

    by Yoichi Mizutani, Akihiro Kawauchi, Benjamin Bonavida, Tsuneharu Miki

  • Open Access

    Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis

    by Yoichi Mizutani, Hiroyuki Nakanishi, Yong Nan Li, Hiroki Matsubara, Kosuke Yamamoto, Nodoka Sato, Takumi Shiraishi, Terukazu Nakamura, Kazuya Mikami, Koji Okihara, et al.

    X-linked inhibitor of apoptosis protein (XIAP) is the most potent caspase-inhibitory IAP family member and a negative regulator of various apoptotic stimuli. Thus, XIAP overexpression in cancer cells may select for tumor cell survival following various cytotoxic therapeutic modalities. The anatomical staging system in renal cell carcinoma (RCC) currently provides good prognostic information, albeit insufficient. We hypothesize that overexpression of XIAP in RCC may serve as a molecular prognostic marker in RCC and improve the staging of RCC. This study examined the protein level of XIAP in lysates from surgical specimens of 109 patients with RCC and 109 normal kidney specimens from the same patients. The level of XIAP expression was quantified by Western blot analysis using non-fixed fresh frozen tissues of RCCs and normal kidneys. Results indicated that the mean level of XIAP expression was higher in RCC compared to autologous normal kidney, and the XIAP expression level in 38/109 (35%) of RCC was more than 2-fold greater than that in normal kidney tissue. In Stage I/II RCC, the mean XIAP expression level was almost identical to that detected in normal kidney, whereas XIAP expression in Stage III/IV was 2.5-fold higher than that in Stage I/II RCC. Levels of XIAP expression also correlated with the grade of RCC. Patients with RCC with low XIAP expression had a longer postoperative disease-specific survival as compared to those with high expression in the 5-year follow-up. The suggested role of XIAP in the regulation of resistance in apoptosis was examined in vitro following treatment of RCC cell lines with XIAP antisense oligonucleotide and the cells were sensitized to both Fas-mediated and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. The present study demonstrates at the protein level that XIAP is overexpressed in RCC, and that high XIAP expression in RCC predicted a worse prognosis. In addition, XIAP antisense oligonucleotide sensitized RCC to Fas/TRAIL-induced apoptosis. These results suggest that XIAP expression in RCC may be used as a prognostic parameter, and that downregulation or inhibition of XIAP expression in RCC may reverse immune resistance.


  • Open Access

    Gene therapy with TRAIL against renal cell carcinoma

    by Hiroki Matsubara, Yoichi Mizutani, Fumiya Hongo, Hiroyuki Nakanishi, Yasunori Kimura, So Ushijima, Akihiro Kawauchi, Takahiro Tamura, Tsuneaki Sakata, Tsuneharu Miki

    Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells. However, TRAIL is not toxic against most normal cells. We have accordingly examined by in vivo electroporation whether TRAIL induces apoptosis in renal cell carcinoma. In addition, combination treatment with TRAIL and 5-fluorouracil (5-FU) against renal cell carcinoma was also investigated. The NC65 renal cell carcinoma line was used as a target. pCAGGS TRAIL was injected into the NC65 tumors in the right flanks of severe combined immunodeficient mice. Tumors were pulsed with the CUY21 electroporator. Electroporation was done once on day 0 or thrice on days 0, 2, and 4. Apoptosis was determined by terminal deoxyribonucleotide transferase–mediated nick-end labeling assay. When TRAIL gene therapy using in vivo i.t. electroporation was done once only, the growth of NC65 tumors was not inhibited. However, when TRAIL gene therapy was done thrice, growth suppression of the NC65 tumors was observed. Transfection of the TRAIL gene by in vivo electroporation induced apoptosis in NC65 tumors. When NC65 cells were treated with TRAIL gene therapy in combination with 5-FU, stronger growth suppression was obtained. TRAIL gene therapy did not induce liver dysfunction in severe combined immunodeficient mice. This study shows that TRAIL gene therapy induced growth suppression and apoptosis in NC65 tumors without severe side effects, and that combination treatment of NC65 cells with TRAIL gene therapy and 5-FU resulted in higher antitumor activity. These findings suggest that TRAIL gene therapy and/or 5-FU may be effective against renal cell carcinoma without harmful toxic effects. [Mol Cancer Ther 2006;5(9):2165–71]


  • Downregulation of Smac/DIABLO Expression in Renal Cell Carcinoma and Its Prognostic Significance

    by Yoichi Mizutani, Hiroyuki Nakanishi, Kosuke Yamamoto, Yong Nan Li, Hiroki Matsubara, Kazuya Mikami, Koji Okihara, Akihiro Kawauchi, Benjamin Bonavida, Tsuneharu Miki

    Purpose: Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) was recently identified as a protein that is released from mitochondria in response to apoptotic stimuli and promotes apoptosis by antagonizing inhibitor of apoptosis proteins. Furthermore, Smac/DIABLO plays an important regulatory role in the sensitization of cancer cells to both immune- and drug-induced apoptosis. However, little is known about the clinical significance of Smac/DIABLO in various cancers, including renal cell carcinoma (RCC). This study examined Smac/DIABLO expression in 78 healthy kidneys and 78 RCCs. Materials and Methods: The level of Smac/DIABLO expression was quantified by Western blot analysis using nonfixed fresh frozen tissues. Results: The expression of Smac/DIABLO was lower in RCC compared with the autologous normal kidney. Sixty-four (82%) of 78 of RCC expressed Smac/DIABLO, and 18% were negative, whereas 100% of normal kidney tissues were positive. In stage I/II RCC, 96% expressed Smac/DIABLO, whereas only 50% expressed Smac/DIABLO in stage III/IV. Smac/DIABLO expression inversely correlated with the grade of RCC. Patients with RCC expressing Smac/DIABLO had a longer postoperative disease-specific survival than those without Smac/DIABLO expression in the 5-year follow-up. Transfection with Smac/DIABLO cDNA enhanced tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) –mediated and cisplatin-mediated cytotoxicity in RCC. Conclusion: The present study demonstrates for the first time that Smac/DIABLO expression was downregulated in RCC and that no Smac/DIABLO expression in RCC predicted a worse prognosis. In addition, transfection with Smac/DIABLO sensitized RCC to TRAIL/cisplatin-induced apoptosis. These results suggest that Smac/DIABLO expression in RCC may be used as a prognostic parameter, and that enhancement of Smac/DIABLO expression in RCC may potentiate immunotherapy and chemotherapy.


  • ENHANCED SENSITIVITY OF BLADDER CANCER CELLS TO CISPLATIN MEDIATED CYTOTOXICITY AND APOPTOSIS IN VITRO AND IN VIVO BY THE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR JTE-522

    by Yoichi Mizutani, Hiroyuki Nakanishi, Yong Nan Li, Nodoka Sato, Akihiro Kawauchi, Tsuneharu Miki

    Purpose: Cyclooxygenase-2 (COX-2) is a key inducible enzyme involved in the production of prostaglandins and its inhibitors have been shown to induce apoptosis in various cancer cells. Seve...


    • 1 April 2003
      • Vol. 9  (4) , 1453-60

    Significance of thymidylate synthase activity in renal cell carcinoma.

    by Yoichi Mizutani, Hiromi Wada, Osamu Yoshida, Masakazu Fukushima, Mitsuo Nonomura, Masahiro Nakao, Tsuneharu Miki

    5-Fluorouracil (5-FU) is an anticancer agent clinically used against various cancers including renal cell carcinoma (RCC). 5-FU inhibits thymidylate synthase (TS) and blocks DNA synthesis. TS is the key enzyme in the catalysis of the methylation from dUMP to dTMP in the DNA synthetic process. Little is known about the significance of TS in RCC. We investigated the activity of TS in 68 RCCs and the association with dihydropyrimidine dehydrogenase (DPD) activities, which is a principal enzyme in the degradation of 5-FU and pyrimidine nucleotides. The relationship between TS/DPD activities in primary cultured RCC cell lines and their sensitivity to 5-FU was also examined. The levels of TS and DPD activities in nonfixed fresh-frozen RCC and normal kidney were determined biochemically by the 5-fluoro-2'-deoxyuridine 5'-monophosphate binding assay and the 5-FU degradation assay, respectively. The sensitivity of primary cultured RCC cells to 5-FU was assessed by the microculture tetrazolium dye assay. The activity of TS was approximately 5-fold higher in RCC compared with normal kidney. TS activity in T(3/4) RCC was 2.5-fold higher than that in T(1/2) RCC. TS activity in M(1) RCC was 2.5-fold higher than that in M(0) RCC. In addition, TS activity in stage III/IV RCC was 3-fold higher than that in stage I/II RCC. The levels of TS activity in grade 3 RCC were 3-fold and 2-fold higher than that in grade 1 and grade 2 cancer, respectively. TS activity in clear cell RCC were 4-fold higher than that in papillary RCC. Patients with low TS activity had a longer disease-specific survival as compared with those with high activity in the 5-year follow-up. There was no relationship between TS and DPD activities. TS activity in primary cultured RCC cells was positively correlated with their sensitivity to 5-FU. Furthermore, RCC cells with both high TS activity and low DPD activity were more sensitive to 5-FU, compared with those with either low TS activity or high DPD activity. The present study is the first study to demonstrate that the level of TS activity was correlated with both the progression of the stage and the increase of the grade of RCC, and that higher TS activity in primary cultured RCC predicted higher sensitivity to 5-FU. These results suggest that high TS activity may be associated with malignant potential of RCC, and that it may be possible to use 5-FU for RCC with high TS activity.


  • Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma

    by Y Mizutani, H Wada, O Yoshida, M Fukushima, H Nakanishi, M Nakao, T Miki


  • Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer.

    by Yoichi Mizutani, Hiromi Wada, Osamu Yoshida, Masakazu Fukushima, Benjamin Bonavida, Akihiro Kawauchi, Tsuneharu Miki

    There is no potent prognostic marker for recurrence in superficial bladder cancer at present. Thymidylate synthase (TS) is a key enzyme for pyrimidine synthesis. Dihydropyrimidine dehydrogenase (DPD) is an important pyrimidine salvage enzyme. We evaluated a combination of TS and DPD activities as a prognostic marker for recurrence in grade 1 and 2 superficial bladder cancer. The levels of TS and DPD activities in non-fixed fresh frozen bladder cancer specimens were determined biochemically by the 5-fluoro-2'-deoxyuridine 5'-monophosphate binding assay and the 5-fluorouracil degradation assay, respectively. Significantly, patients with low TS activity and high DPD activity had a longer post-operative tumor-free interval than those with either high TS activity or low DPD activity in the 2-year follow-up. There were no statistical differences observed in patient's sex and age as well as the histologic stage and grade of bladder cancer between the two groups. In addition, there is no correlation between TS and DPD activities. The present study suggests that a combination of TS and DPD activities may be an independent prognostic indicator for recurrence in grade 1 and 2 superficial bladder cancer, and that either high TS activity or low DPD activity predicts early recurrence.


  • Cisplatin‐induced in vivo differentiation of human embryonal carcinoma

    by Y. Mizutani, N. Sato, A. Kawauchi, N. Nonomura, M. Fukushima, T. Miki

    Objective To investigate the differentiation of embryonal carcinoma (EC) by cisplatin, and the underlying mechanism, as untreated metastases of nonseminomatous germ cell tumours rarely consist of fully differentiated mature somatic tissues, but such mature metastases are more common after various treatments, including chemotherapy. Materials and methods The TTSC‐3 human testicular EC line heterotransplanted into nude mice was used as a target. After treating tumour‐bearing mice with intraperitoneal injections of varying doses of cisplatin, the histopathology of the tumours was assessed and various gene expressions in the tumours determined by cDNA‐array technology. Results When cisplatin at 1 mg/kg/week was injected intraperitoneally into TTSC‐3‐bearing mice, there was no effect on tumour growth. However, injecting cisplatin at 5 mg/kg/week induced a marked regression of the tumour. In contrast, cisplatin at 3 mg/kg/week had a modest inhibitory effect on tumour growth and induced tumour dormancy. Histological examination showed that 5 weeks after injecting cisplatin (3 mg/kg/week), primitive mesenchymal‐like cells increased, and 10 weeks afterward cartilage and well‐developed glands (teratoma) were apparent; at > 15 weeks afterward there were no EC cells visible. cDNA probes from reverse‐transcribed mRNAs of TTSC‐3 treated with cisplatin or saline for 10 weeks were compared to identify genes differentially expressed in cisplatin‐treated TTSC‐3. Of 1176 different human cDNA transcripts in cisplatin‐treated TTSC‐3, three genes (tumour necrosis factor receptor 1, caspase 8 and Apaf1 ), which are associated with apoptosis, were expressed markedly more than after saline injection. Conclusions The intermediate dose of cisplatin inhibited tumour growth of EC by inducing differentiation and enhancing apoptosis‐related gene expression. These findings suggest that cisplatin may play a significant role in the differentiation of EC in vivo .